Pregabalin has been approved for the treatment of the neuropathic pain following spinal cord injury (SCI). We performed a systemic review and meta-analysis of randomized, controlled, multicenter trials to evaluate the efficacy and safety of pregabalin for SCI-induced neuropathic pain.
Research searching was performed in PubMed and EMBASE databases and the Cochrane library in May 2018. Clinical controlled trials using pregabalin for the pain treatment following SCI in adults (18 y old and above) were included. Pain and safety-related adverse events were considered as outcomes. Meta-analysis was conducted using Revman 5.0 software.
Five publications (pregabalin, patients=261, placebo, patients=216) were included in our study. After at least 4-week’s treatment with pregabalin (flexible dose, 150 to 600 mg/d), pregabalin-treated patients showed reduced pain −1.54, 95% confidence interval (CI) (−2.33, −0.75), P=0.0001; improved >30% 1.83, 95% CI (1.37, 2.46), P<0.0001 and >50% pain relief 2.40, 95% CI (1.53, 3.77), P=0.0001; increased adverse events 1.36, 95% CI (1.18, 1.577), P<0.0001; and reduced Hospital Anxiety and Depression Scale - anxiety −1.50, 95% CI (−2.99, −0.00), P=0.05 and - depression −0.34, 95% CI (−0.55, −0.12), P=0.002 scores compared with placebo-treated patients. Stratified meta-analysis showed there was no difference in primary adverse events (drowsiness, dizziness, peripheral edema, and dry mouth) between pregabalin and placebo groups (P≥0.05).
Our results showed pregabalin was efficacious and might be safe treatment for chronic pain followed SCI.
*Department of Orthopaedics
†Postdoctoral Workstation, Zhongshan Hospital of Dalian University, Dalian
‡Institute of Metal Research, Chinese Academy of Science, Shenyang, China
X.Y. and T.L. contributed equally.
X.Y., K.Y., and D.Z.: conceived and designed the study. B.W., X.Z., and M.Z.: performed the experiments. S.Z.: provided the mutants. T.L. and B.W.: wrote the paper. W.H., T.L., and J.L.: reviewed and edited the manuscript.
The authors declare no conflict of interest.
Reprints: Xiaobing Yu, MD, No. 6, Jiefang Street, Dalian, Liaoning province 116001, China (e-mail: email@example.com).
Received August 21, 2018
Received in revised form October 19, 2018
Accepted November 11, 2018